RxDoctor Payments Data

Jonathan Mercer, MD

Urology · Kalispell, MTNPI 1992746192

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Coloplast at 38.4% of the total. Reporting peaked in 2020 at $757 and has fallen 79.1% since, to $158 in 2025. That places this record below the midpoint for urology clinicians in MT, where the typical reported total is $1,996.

$1,779in general payments, 2019–2025

Across 28 payments — averaging $63.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$683
  • Astellas Pharma US Inc$233
  • EMD Serono, Inc.$175
  • Comsort, Inc$100
  • Healthtronics Stone Solutions, LLC$87
  • Axonics, Inc.$79
  • plus $423 from 12 others

What the payments were for

  • Consulting fees$1006%
  • Travel & lodging$68338%
  • Food & beverage$84347%
  • Education$1539%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,779 in reported general payments places this provider in the 45th percentile of 45 urology providers in Montana.

See all urology providers in Montana

Medicare billing

Part B allowed, 2024
$79,900
Medicare patients
161
Services billed
2,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron55$50,666
GemtesaVibegron22$17,214
PremarinEstrogens, Conjugated13$5,792
Tamsulosin Hcl340$5,445
Potassium Citrate ErPotassium Citrate21$2,997
Estradiol21$1,404
Silodosin21$894
Finasteride57$817
Oxybutynin Chloride106$800
Testosterone Cypionate14$730
CefuroximeCefuroxime Axetil30$476
Alfuzosin Hcl ErAlfuzosin Hcl20$437
Ciprofloxacin Hcl51$388
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen59$284
Doxycycline Hyclate14$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$233$50,66655 claims
Sumitomo Pharma America, Inc.Gemtesa$15$17,21422 claims
PfizerPremarin$13$5,79213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 45 urology providers in Montana.

Other urology in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →